Weekly Research Analysts’ Ratings Changes for La Jolla Pharmaceutical (LJPC)

A number of firms have modified their ratings and price targets on shares of La Jolla Pharmaceutical (NASDAQ: LJPC) recently:

  • 2/15/2018 – La Jolla Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. “
  • 2/15/2018 – La Jolla Pharmaceutical was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 2/12/2018 – La Jolla Pharmaceutical was downgraded by analysts at Jefferies Group LLC from a “buy” rating to an “underperform” rating. They now have a $29.00 price target on the stock, down previously from $40.00.
  • 2/9/2018 – La Jolla Pharmaceutical was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 2/2/2018 – La Jolla Pharmaceutical was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 1/25/2018 – La Jolla Pharmaceutical had its price target raised by analysts at Chardan Capital from $90.00 to $100.00. They now have a “buy” rating on the stock. They wrote, “We see La Jolla Pharmaceutical as a remarkably de-risked rare disease story, and thus one deserving of higher conviction now, than the high conviction we had a year ago. With our 24 January 2017 research, we made La Jolla a Chardan Top Pick for 2017 based on (1) La Jolla’s approach being one of the more compelling and convincing rare disease strategies in biotech…[due to] focusing on naturally-occurring peptides with well-established biological functions” and (2) confidence the company will produce positive [pivotal Giapreza] ATHOS-3 phase III results” in 1Q17.””
  • 1/23/2018 – La Jolla Pharmaceutical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/10/2018 – La Jolla Pharmaceutical was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 12/29/2017 – La Jolla Pharmaceutical had its price target raised by analysts at HC Wainwright from $62.00 to $91.00. They now have a “buy” rating on the stock.
  • 12/28/2017 – La Jolla Pharmaceutical was given a new $65.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 12/27/2017 – La Jolla Pharmaceutical was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/26/2017 – La Jolla Pharmaceutical was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 12/22/2017 – La Jolla Pharmaceutical had its “sell” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 12/22/2017 – La Jolla Pharmaceutical had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $55.00 price target on the stock.
  • 12/22/2017 – La Jolla Pharmaceutical had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $90.00 price target on the stock.
  • 12/22/2017 – La Jolla Pharmaceutical had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $65.00 price target on the stock, down previously from $67.00.
  • 12/21/2017 – La Jolla Pharmaceutical was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 12/21/2017 – La Jolla Pharmaceutical is now covered by analysts at HC Wainwright. They set a “buy” rating and a $62.00 price target on the stock.

La Jolla Pharmaceutical (LJPC) traded down $0.35 during mid-day trading on Thursday, reaching $32.73. The company had a trading volume of 386,800 shares, compared to its average volume of 488,538. La Jolla Pharmaceutical has a fifty-two week low of $16.71 and a fifty-two week high of $41.36. The firm has a market capitalization of $732.57, a P/E ratio of -6.42 and a beta of 1.20.

In other La Jolla Pharmaceutical news, Director Laura L. Douglass sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $32.32, for a total transaction of $323,200.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at $193,920. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Jennifer Carver purchased 1,000 shares of the business’s stock in a transaction on Wednesday, December 27th. The shares were acquired at an average price of $33.22 per share, with a total value of $33,220.00. Following the purchase, the chief operating officer now owns 4,500 shares of the company’s stock, valued at $149,490. The disclosure for this purchase can be found here. 25.47% of the stock is owned by company insiders.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply